Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues

Agios Pharmaceuticals (AGIO) incurred a loss of $1.74 per share in the fourth quarter of 2024, wider than the Zacks Consensus Estimate of a loss of$1.73. In the year-ago quarter, the company had reported a loss per share of $1.72.See the Zacks Earnings Calendar to stay ahead of market-making news.AGIO reported revenues of$10.7 million for the fourth quarter, which marginally beat the Zacks Consensus Estimate of $10 million. Revenues increased 51$7.1 million.In the p ...